Biosimulation Market Trends and Growth Strateges 2026-2031 | Industry to Reach $9.24 Billion by 2031, Driven by Model-Informed Drug Development and AI Adoption
Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Biosimulation Market by Phase, Modality, Application, Indication, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.
The global biosimulation market is projected to grow from USD 4.27 billion in 2026 to USD 9.24 billion by 2031, registering a compound annual growth rate of 16.7% during the forecast period. Market expansion is being driven by increasingly complex drug discovery and development programs, pressure to improve pharmaceutical R&D productivity, and demand for predictive modeling approaches that can reduce late-stage clinical failures.
Pharmaceutical and biotechnology companies are expanding their use of biosimulation software and services to assess drug candidates, optimize dosing strategies, predict safety and efficacy outcomes, and support regulatory decisions before compounds advance into resource-intensive laboratory and clinical studies. Continued growth in pharmaceutical R&D spending, combined with the integration of artificial intelligence, machine learning, and digital drug development technologies, is accelerating demand for advanced biosimulation platforms.
Regulatory acceptance of model-informed drug development is also supporting market growth. In January 2025, the International Council for Harmonisation reached Step 4 adoption of the ICH M15 Guideline on Model-Informed Drug Development, establishing a harmonized framework for applying modeling and simulation within drug development programs and regulatory submissions.
Market expansion may be limited by high software implementation and model development costs, insufficient standardization, data availability and quality issues, model validation requirements, and integration challenges across diverse research environments. The shortage of pharmacometricians, computational scientists, and biosimulation and modeling experts also remains a significant industry constraint. Additional challenges include accurately representing the complexity of biological systems and processes.
Pharmaceutical and Biotechnology Companies Led the Market in 2025
Pharmaceutical and biotechnology companies accounted for the largest biosimulation market share by end user in 2025. These organizations use biosimulation across compound screening, translational research, exposure-response analysis, clinical trial optimization, and regulatory interactions to improve development efficiency and increase the probability of clinical success.
Growing investment in biologics, gene therapies, mRNA-based therapeutics, precision medicine, and other innovative modalities has increased reliance on advanced modeling and simulation. The need to reduce drug attrition, accelerate time to market, manage complex therapeutic pipelines, and maximize returns on R&D investments is expected to sustain the segment's market leadership.
Cloud-Based Biosimulation Models to Record the Fastest Growth
Cloud-based models are expected to be the fastest-growing deployment segment through 2031. Adoption is supported by demand for scalable computing capacity, collaborative research environments, faster model deployment, and cost-effective access to sophisticated simulation capabilities.
Cloud platforms allow organizations to conduct physiologically based pharmacokinetic modeling, quantitative systems pharmacology, molecular dynamics, AI-driven drug discovery, and virtual patient simulations without substantial investment in on-premises infrastructure. They also improve data sharing and collaboration among geographically distributed research teams. Integration with artificial intelligence, machine learning, and high-performance computing is further increasing adoption, particularly among small and mid-sized organizations seeking greater flexibility and lower operating costs.
Asia Pacific Positioned as the Fastest-Growing Regional Market
Asia Pacific is projected to register the highest biosimulation market growth rate during the forecast period. Regional expansion is being supported by increasing pharmaceutical and biotechnology R&D activity, adoption of AI-driven drug discovery, demand for cost-effective development strategies, and investment in computational biology and precision medicine.
China, India, Japan, South Korea, and Singapore are strengthening their life sciences ecosystems through government-backed innovation programs, expanded biopharmaceutical manufacturing, and broader use of modeling and simulation throughout research workflows. The growing presence of global pharmaceutical companies, contract research organizations, and academic research institutes is also accelerating regional platform adoption.
In May 2025, Insilico Medicine announced the global expansion of its research and development operations to advance AI-powered drug discovery and development. The development reinforces Asia Pacific's position as an important center for computational life sciences and biosimulation innovation.
Competitive Landscape
Leading biosimulation market players include Certara of the US, Dassault Systemes of France, Schrodinger, Inc. of the US, Simulations Plus of the US, and Advanced Chemistry Development, Inc. (Revvity) of Canada. Competitive assessment covers market shares, growth strategies, product and service portfolios, business capabilities, contracts, partnerships, agreements, product launches, service launches, mergers and acquisitions, investments, and other recent developments. The research also evaluates emerging startups within the biosimulation ecosystem.
Market Segmentation and Research Coverage
The report segments the biosimulation market by offering into software and services. Development phases include drug discovery, preclinical development, early clinical development, late clinical development, regulatory activities, and commercial and market access. Modalities include antibody design, peptide discovery, enzyme engineering, bifunctional degraders, T-cell receptor modeling, and other modalities.
Applications covered include molecular design and optimization, pharmacokinetic and pharmacodynamic modeling, physiologically based pharmacokinetic modeling, quantitative systems pharmacology, absorption, distribution, metabolism, excretion and toxicity prediction, clinical trial simulation, disease modeling, and other applications. Therapeutic areas include oncology, cardiovascular diseases, neurological disorders, infectious diseases, metabolic and endocrine disorders, and other therapeutic areas.
Deployment modes comprise on-premises, cloud-based, and hybrid models. End users include pharmaceutical and biotechnology companies, contract research organizations, academic and research institutes, regulatory bodies, and other organizations. Regional coverage includes North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Key Attributes
MARKET DYNAMICS
COMPANY PROFILES
For more information about this report visit https://www.researchandmarkets.com/r/o1o09q
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment